Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 72.25B | 65.18B | 59.42B | 53.26B | 49.00B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.25B | 65.18B | 59.42B | 53.26B | 49.00B |
| Cost of Revenue | 12.40B | 11.05B | 10.08B | 9.25B | 8.97B |
| Gross Profit | 59.84B | 54.13B | 49.34B | 44.01B | 40.03B |
| SG&A Expenses | 11.67B | 11.20B | 10.51B | 9.87B | 9.23B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.18B | 35.59B | 33.16B | 30.94B | 29.40B |
| Operating Income | 34.07B | 29.59B | 26.26B | 22.31B | 19.61B |
| Income Before Tax | 31.13B | 25.73B | 22.50B | 16.86B | 13.60B |
| Income Tax Expenses | 5.85B | 5.09B | 4.09B | 3.06B | 2.49B |
| Earnings from Continuing Operations | 25.28K | 20.64K | 18.41K | 13.80K | 11.11K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.28B | 20.64B | 18.41B | 13.80B | 11.11B |
| EBIT | 34.07B | 29.59B | 26.26B | 22.31B | 19.61B |
| EBITDA | 36.11B | 31.59B | 28.16B | 24.21B | 21.44B |
| EPS Basic | 28.19 | 22.99 | 20.48 | 15.33 | 12.32 |
| Normalized Basic EPS | 23.44 | 20.17 | 17.82 | 15.14 | 13.36 |
| EPS Diluted | 28.15 | 22.95 | 20.44 | 15.30 | 12.29 |
| Normalized Diluted EPS | 23.41 | 20.14 | 17.79 | 15.11 | 13.32 |
| Average Basic Shares Outstanding | 3.59B | 3.59B | 3.60B | 3.60B | 3.60B |
| Average Diluted Shares Outstanding | 3.59B | 3.60B | 3.60B | 3.61B | 3.61B |
| Dividend Per Share | 6.23 | 6.00 | 5.80 | 5.60 | 5.40 |
| Payout Ratio | 22.10% | 26.08% | 28.28% | 36.46% | 43.73% |